title: [Efficacy evaluation of heat-sensitive moxibustion for chemotherapy symptoms of large intestine cancer].
abstract: OBJECTIVE
  To analyze and evaluate the clinical efficacy of heat-sensitive moxibustion for symptoms of large intestine cancer.
  
  
  METHODS
  Sixty patients with large intestine cancer were randomly divided into an observation group and a control group, 30 cases in each one. FOLFOX chemotherapy regimen was used in the two groups,and heat-sensitive moxibustion was added in the observation group. The acupoints were Zusanli(ST 36), Sanyinjiao (SP 6) Xuehai (SP 10) and Geshu (BL 17), etc. The treatment was applied once a day,five-day treatment as one course. Four courses were required. The reaction rates of uncomfortable symptoms by the Chinese version of the M. D. Anderson symptom inventory (MDASI-C) scale and clinical effects were analyzed and evaluated in the two groups.
  
  
  RESULTS
  After treatment, the MDASI-C reaction rate of uncomfortable symptoms in the observation group was 50.4% which was lower than 53.3% in the control group (P < 0.05). The total effective rate of symptom improvement in the observation group was 83.3% (25/30), which was higher than 60.0% (18/30) in the control group (P < 0.05).
  
  
  CONCLUSIONS
  Heat-sensitive moxibustion can improve symptoms of chemotherapy for large intestine cancer.
authors.forename: Zhiping
authors.initials: Z
authors.lastname: Li
authors.forename: Zhi
authors.initials: Z
authors.lastname: Zheng
authors.forename: Lijun
authors.initials: L
authors.lastname: Wang
authors.forename: Weiyun
authors.initials: W
authors.lastname: Xiao
authors.forename: Jiquan
authors.initials: J
authors.lastname: Zeng
authors.forename: Jing
authors.initials: J
authors.lastname: Hao
authors.forename: Rixin
authors.initials: R
authors.lastname: Chen
authors.forename: Dingyi
authors.initials: D
authors.lastname: Xie
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology / Q000628:therapy*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007420:Intestine, Large / Q000187:drug effects*; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009071:Moxibustion / Q000295:instrumentation; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil